Sorrento Therapeutics, Inc. (SRNE)
SRNE Stock Price Chart
Explore Sorrento Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze SRNE price movements and trends.
SRNE Company Profile
Discover essential business fundamentals and corporate details for Sorrento Therapeutics, Inc. (SRNE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jan 2007
Employees
949.00
CEO
Henry H. Ji
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
SRNE Financial Timeline
Browse a chronological timeline of Sorrento Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 11 Feb 2025
Earnings released on 27 Dec 2024
Earnings released on 16 Aug 2024
Earnings released on 20 May 2024
Earnings released on 28 Feb 2024
Earnings released on 3 Nov 2023
Earnings released on 12 Aug 2023
EPS came in at -$0.17 falling short of the estimated -$0.15 by -15.14%, while revenue for the quarter reached $15.03M , missing expectations by -33.52%.
Earnings released on 15 May 2023
EPS came in at -$0.26 falling short of the estimated -$0.16 by -60.66%, while revenue for the quarter reached $16.25M , missing expectations by -18.75%.
Earnings released on 15 Mar 2023
EPS came in at -$0.34 falling short of the estimated -$0.19 by -79.76%, while revenue for the quarter reached $62.84M , beating expectations by +244.81%.
Earnings released on 8 Nov 2022
EPS came in at -$0.20 surpassing the estimated -$0.25 by +20.00%, while revenue for the quarter reached $17.40M , beating expectations by +27.99%.
Earnings released on 15 Aug 2022
EPS came in at -$0.31 falling short of the estimated -$0.23 by -34.78%, while revenue for the quarter reached $11.46M , missing expectations by -38.88%.
Earnings released on 5 May 2022
EPS came in at -$0.12 surpassing the estimated -$0.25 by +52.00%, while revenue for the quarter reached $18.39M , missing expectations by -6.93%.
Earnings released on 11 Mar 2022
EPS came in at -$0.47 falling short of the estimated -$0.29 by -62.07%, while revenue for the quarter reached $13.08M , beating expectations by +0.58%.
Earnings released on 5 Nov 2021
EPS came in at -$0.40 falling short of the estimated -$0.21 by -90.48%, while revenue for the quarter reached $12.06M , beating expectations by +25.70%.
Earnings released on 6 Aug 2021
EPS came in at -$0.33 falling short of the estimated -$0.20 by -65.00%, while revenue for the quarter reached $13.51M , beating expectations by +15.44%.
Earnings released on 5 May 2021
EPS came in at $0.01 falling short of the estimated $0.38 by -97.37%, while revenue for the quarter reached $14.26M , missing expectations by -43.70%.
Earnings released on 19 Feb 2021
EPS came in at -$0.27 falling short of the estimated -$0.23 by -17.39%, while revenue for the quarter reached $11.51M , missing expectations by -47.07%.
Earnings released on 6 Nov 2020
EPS came in at -$0.33 falling short of the estimated -$0.25 by -32.00%, while revenue for the quarter reached $11.75M , beating expectations by +15.44%.
SRNE Stock Performance
Access detailed SRNE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.